|

CTSN Embolic Protection Trial

RECRUITINGN/ASponsored by Icahn School of Medicine at Mount Sinai
Actively Recruiting
PhaseN/A
SponsorIcahn School of Medicine at Mount Sinai
Started2023-09-18
Est. completion2027-04-01
Eligibility
Age60 Years+
Healthy vol.Accepted
Locations24 sites

Summary

This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.

Eligibility

Age: 60 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥ 60 years
* Planned de novo or redo:

  * Surgical aortic valve replacement SAVR ± ascending aortic repair (if circulatory arrest is not required) ± CABG
  * Mitral valve replacement (MVR) ± CABG
  * Mitral Valve Repair + CABG,
  * Double/Triple valve surgery ± CABG; Ross procedure These procedures can be done via a full or minimal-access sternotomy (using central aortic perfusion cannulae) with legally marketed valve(s), and can be done in combination with an left atrial appendage (LAA) closure/excision or partial/complete Maze procedure.
  * Valve sparing aortic root replacement (David procedure)
  * Valve sparing aortic root replacement (David procedure)
* No evidence of neurological impairment as defined by a NIHSS ≤1 and modified Rankin scale (mRS) ≤2 within 30 days prior to randomization
* Ability to provide informed consent and comply with the protocol

Exclusion Criteria:

* History of clinical stroke within 3 months prior to randomization
* Cerebral and or aortic arch arteriography or interventions within 3 days of the planned procedure
* Coronary catheterization within 3 days of index procedure, and the required repeat NIHSS score post-catheterization is worse than the screening/baseline NIHSS score conducted prior to the catheterization
* Active endocarditis at time of randomization with vegetation criteria
* Clinical signs of cardiogenic shock or treatment with IV inotropic therapy prior to randomization
* Participation in an interventional (drug or device) trial
* Isolated mitral valve repair, isolated tricuspid valve repair or combined mitral valve repair and tricuspid valve repair
* Anticipated requirement for prolonged mechanical ventilation greater than 48 hours after surgery in the opinion of the investigator
* Planned concomitant carotid endarterectomy during index surgical procedure

Conditions6

Acute Kidney InjuryCoronary Artery DiseaseDeliriumHeart DiseaseHeart Valve DiseaseIschemic Stroke

Locations24 sites

CHI St. Vincent Heart Institute
North Little Rock, Arkansas, 72117
Keck Hospital of the University of Southern California
Los Angeles, California, 90033
Emory University
Atlanta, Georgia, 30322
Sonya Mathewsonsbmathe@emory.edu
Indiana University
Bloomington, Indiana, 47405
Srdjan Kurbalijaskurbalija@iuhealth.org
Indiana Ohio Heart
Fort Wayne, Indiana, 46804

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.